Compare BIO-TECHNE Corp (TECH) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Clear Secure Inc — how do they compare? BIO-TECHNE Corp trades at $72.14 (market cap $11.24B), while Clear Secure Inc trades at $48.44 (market cap $5.28B). The key difference: BIO-TECHNE Corp is far larger — about 2.1× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.12%). Which is the better fit depends on your goals.
| TECH | YOU | |
|---|---|---|
Market Cap | $11.24B | $5.28B |
Sector | Health | Technology |
52-Week High | $72.29 | $62.36 |
52-Week Low | $43.31 | $29.61 |
Enterprise Value | $11.32B | $4.43B |
Dividend Yield | 0.44% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Clear Secure (YOU) trades at $51.29, down 3.26% in 24 hours, with a bearish technical signal but strong fundamentals including 66.66% gross margins and 90.29% ROE. Recent Q2 2026 earnings beat estimates with EPS of $0.49 versus $0.40 expected, driven by double-digit revenue growth and record free cash flow. The company launched corporate memberships to expand its identity platform, enhancing business travel offerings.
Outlook is mixed: robust profitability and growth initiatives support upside, but high valuation (P/E 34.6) and technical weakness near support at $50 pose risks. Analyst consensus is balanced with 44% buy ratings, yet insider selling and competitive pressures require caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
